A groundbreaking mRNA-based vaccine, utilizing the same technology as COVID-19 shots, significantly reduces the risk of recurrence or death from melanoma. This personalized vaccine, intismeran, targets the unique genetic profile of a patient's skin cancer. When combined with the existing drug Keytruda, it lowered the risk of melanoma returning or patient death by 42%. The randomized Phase III trial involved 1,137 high-risk patients who had undergone surgical removal of their melanoma. Patients receiving intismeran plus Keytruda showed superior recurrence-free survival compared to those on Keytruda and a placebo. This individualized approach marks a fundamental shift in cancer treatment, moving beyond tumor origin. While focusing on melanoma, researchers are also exploring mRNA technology for other cancers like lung, breast, and prostate. Early studies on breast cancer have shown promising results with personalized mRNA vaccines. Despite investor reactions, scientists are highly optimistic about mRNA's potential to revolutionize cancer therapy. The full trial results were prematurely released due to a leak, causing a temporary dip in Moderna's stock. However, the scientific community views these findings as a major leap forward.